RP Bio Inc. (KOSDAQ:314140)
South Korea · Delayed Price · Currency is KRW 5,780.00
+190.00 (3.40%)
At close: Aug 24, 2026
RP Bio Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 50,092 | 64,131 | 43,765 | 74,964 | 102,515 | - | |
Market Cap Growth | -7.37% | 46.53% | -41.62% | -26.88% | - | - |
Enterprise Value | 49,572 | 68,636 | 58,375 | 92,754 | 118,331 | - |
Last Close Price | 5780.00 | 7400.00 | 5015.60 | 8591.08 | 12389.51 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 7.44 | 13.70 | - | 13.79 | 23.75 | - |
PS Ratio | 0.35 | 0.47 | 0.35 | 0.50 | 0.74 | - |
PB Ratio | 0.43 | 0.60 | 0.43 | 0.73 | 1.13 | - |
P/TBV Ratio | 0.43 | 0.60 | 0.43 | 0.73 | 1.13 | - |
P/FCF Ratio | 6.23 | 8.81 | 5.71 | - | - | - |
P/OCF Ratio | 4.20 | 5.14 | 3.24 | 7.09 | 88.76 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.35 | 0.50 | 0.47 | 0.61 | 0.86 | - |
EV/EBITDA Ratio | 3.66 | 5.97 | 9.53 | 7.32 | 7.86 | - |
EV/EBIT Ratio | 6.64 | 13.50 | - | 14.01 | 12.27 | - |
EV/FCF Ratio | 6.16 | 9.43 | 7.61 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.17 | 0.18 | 0.30 | 0.30 | 0.42 | 0.59 |
Debt / EBITDA Ratio | 1.42 | 1.69 | 4.93 | 2.43 | 2.54 | 3.64 |
Debt / FCF Ratio | 2.39 | 2.67 | 3.94 | - | - | 18.23 |
Net Debt / Equity Ratio | 0.00 | 0.05 | 0.11 | 0.18 | 0.22 | 0.47 |
Net Debt / EBITDA Ratio | -0.04 | 0.42 | 1.86 | 1.44 | 1.32 | 2.94 |
Net Debt / FCF Ratio | -0.06 | 0.66 | 1.48 | -33.54 | -4.98 | 14.74 |
Asset Turnover | 0.86 | 0.86 | 0.76 | 0.89 | 0.87 | 0.84 |
Inventory Turnover | 4.44 | 5.09 | 4.02 | 3.73 | 3.94 | 5.24 |
Quick Ratio | 0.80 | 0.75 | 0.71 | 0.57 | 0.50 | 0.41 |
Current Ratio | 1.42 | 1.30 | 1.19 | 1.18 | 1.03 | 0.73 |
Return on Equity (ROE) | 6.07% | 4.47% | -0.89% | 5.61% | 5.39% | 5.73% |
Return on Assets (ROA) | 2.84% | 2.01% | -0.27% | 2.44% | 3.81% | 2.68% |
Return on Invested Capital (ROIC) | 6.18% | 4.50% | -0.59% | 5.49% | 6.91% | 5.32% |
Return on Capital Employed (ROCE) | 6.20% | 4.50% | -0.60% | 6.10% | 10.20% | 8.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 13.43% | 7.30% | -2.07% | 7.25% | 4.21% | - |
FCF Yield | 16.06% | 11.34% | 17.53% | -0.73% | -3.89% | - |
Buyback Yield / Dilution | -0.20% | -0.12% | 7.53% | -31.19% | -8.34% | 1.16% |